Palatin Technologies Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Palatin Technologies de 64.9% y 55.1% respectivamente, mientras que el BPA crecerá en un 67.7% al año.

Información clave

64.9%

Tasa de crecimiento de los beneficios

67.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	25.3%
Tasa de crecimiento de los ingresos	55.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0KF3 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	43	-12	N/A	N/A	2
6/30/2025	7	-21	N/A	-27	2
6/30/2024	4	-27	N/A	-30	3
12/31/2023	7	-35	-17	-27	N/A
9/30/2023	6	-25	-26	-26	N/A
6/30/2023	5	-28	-29	-28	N/A
3/31/2023	4	-25	-28	-27	N/A
12/31/2022	3	-26	-36	-35	N/A
9/30/2022	2	-37	-32	-32	N/A
6/30/2022	1	-36	-30	-30	N/A
3/31/2022	1	-37	-31	-31	N/A
12/31/2021	1	-35	-25	-25	N/A
9/30/2021	0	-37	-33	-33	N/A
6/30/2021	0	-34	-23	-23	N/A
3/31/2021	0	-27	-20	-20	N/A
12/31/2020	0	-27	-19	-19	N/A
9/30/2020	0	-22	-10	-10	N/A
6/30/2020	0	-22	41	41	N/A
3/31/2020	60	37	40	40	N/A
12/31/2019	60	37	39	39	N/A
9/30/2019	60	37	38	39	N/A
6/30/2019	60	36	-22	-22	N/A
3/31/2019	21	-5	-4	-4	N/A
12/31/2018	30	0	-8	-8	N/A
9/30/2018	40	8	-5	-5	N/A
6/30/2018	67	25	2	2	N/A
3/31/2018	80	26	-22	-22	N/A
12/31/2017	82	23	29	29	N/A
9/30/2017	72	10	N/A	21	N/A
6/30/2017	45	-13	N/A	13	N/A
3/31/2017	11	-40	N/A	12	N/A
12/31/2016	N/A	-49	N/A	-42	N/A
9/30/2016	N/A	-52	N/A	-45	N/A
6/30/2016	N/A	-52	N/A	-47	N/A
3/31/2016	N/A	-50	N/A	-43	N/A
12/31/2015	N/A	-47	N/A	-38	N/A
9/30/2015	8	-31	N/A	-28	N/A
6/30/2015	13	-18	N/A	-13	N/A
3/31/2015	13	-10	N/A	-8	N/A
12/31/2014	13	-2	N/A	-5	N/A
9/30/2014	5	-9	N/A	-4	N/A
6/30/2014	N/A	-14	N/A	-12	N/A
3/31/2014	N/A	-14	N/A	-13	N/A
12/31/2013	N/A	-17	N/A	-15	N/A
9/30/2013	0	-15	N/A	-11	N/A
6/30/2013	0	-21	N/A	-14	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 0KF3 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 0KF3 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 0KF3 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (55.1% al año) de 0KF3 crezcan más rápidamente que los del mercado UK (3.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (55.1% al año) de 0KF3 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 0KF3 se prevé que sea elevada dentro de 3 años.

Palatin Technologies Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Recent updates

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024

No longer forecast to breakeven

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.13 loss in 2Q 2023)

Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million.

Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024

Forecast to breakeven in 2026

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.86 loss in 1Q 2023)

New major risk - Negative shareholders equity

Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding

Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Full year 2023 earnings released: US$2.53 loss per share (vs US$3.79 loss in FY 2022)

Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023

Insufficient new directors

Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease

Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Third quarter 2023 earnings released: US$0.63 loss per share (vs US$0.80 loss in 3Q 2022)

Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023

Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Insufficient new directors

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.91 loss in 2Q 2022)

Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023

Insufficient new directors

Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

Forecast to breakeven in 2025

Insufficient new directors

Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million.

Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177

Insufficient new directors

Full year 2022 earnings released: US$3.79 loss per share (vs US$3.55 loss in FY 2021)

Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Insufficient new directors

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Third quarter 2022 earnings released: US$0.032 loss per share (vs US$0.024 loss in 3Q 2021)

Palatin Technologies, Inc. to Report Q3, 2022 Results on May 17, 2022

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Palatin Technologies, Inc. to Report Q2, 2022 Results on Feb 15, 2022

Palatin Technologies, Inc. Announces Initiation of Pivotal Phase 3 Pl9643 Melody-1 Clinical Trial in Patients with Dry Eye Disease

First quarter 2022 earnings released: US$0.03 loss per share (vs US$0.017 loss in 1Q 2021)

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.096 loss in FY 2020)

Insufficient new directors

Palatin Technologies, Inc. Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Palatin Technologies, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease

Palatin Technologies, Inc. Announces U.S. Patent Term Extension for Vyleesi

Revenue misses expectations

Palatin Technologies, Inc. to Report Q2, 2021 Results on Feb 17, 2021

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento